Search alternatives:
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
4081
-
4082
-
4083
-
4084
-
4085
-
4086
-
4087
-
4088
-
4089
Combination metabolic therapy decreases VM-M3 cell proliferation <i>in vitro</i>.
Published 2015“…Cell density was measured with trypan blue hemocytometry to produce a growth curve over 96 hours. <b>(A)</b> Proliferation of VM-M3 cells was inhibited with decreasing glucose concentration and the addition of HBOT. …”
-
4090
-
4091
Modulation of Nogo-A and CaM Kinase II protein levels by running wheel exercise in primary motor cortex.
Published 2021“…After 7 days of exercise, Nogo-A protein levels significantly decreased in M1 L2/3 (***: <i>P</i> = 0.001), but not in M1 L5 (a). …”
-
4092
-
4093
Loss of Pcgf5 results in reduction in global H2AK119 levels.
Published 2016“…<p>(A) H2AK119ub1 levels in LK cells. LK cells from BM of WT and <i>Pcgf5</i><sup><i>Δ/Δ</i></sup> mice were analyzed by Western blotting using anti-H2AK119ub1 and anti-H3K27me3 antibodies at 1-month post deletion of <i>Pcgf5</i>. …”
-
4094
-
4095
-
4096
-
4097
-
4098
-
4099
Combination metabolic therapy decreases VM-M3 cell viability <i>in vitro</i>.
Published 2015“…<b>(A-B)</b> βHB, LG, and LG+βHB+HBOT treatment decreased viability compared to control and HBOT treated cells. …”
-
4100
Inhibition of SHP-2 activity decreases <i>C</i>. <i>parvum</i> infectivity.
Published 2015“…<p>A) Dose-dependent decrease of Infections per field of view (y-axis) after treatment of FHs 74 Int cells with increasing concentrations of the SHP-2-specific inhibitor, SHP-2 PTPase Inhibitor. …”